Get the Stockscreener App
1.67
2.34%
-0.04
Artelo Biosciences Inc stock is traded at $1.67, with a volume of 26,791.
It is down -2.34% in the last 24 hours and down -51.59% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
26,791
Relative Volume:
0.14
Market Cap:
$3.37M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.5285
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
-9.73%
1M Performance:
-51.59%
6M Performance:
-70.78%
1Y Performance:
-75.37%
1-Day Range:
$1.552
$1.75
1-Week Range:
$1.552
$1.97
52-Week Range:
$1.552
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.67 | 3.45M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences Inc. stock trend forecast2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Regression analysis insights on Artelo Biosciences Inc. performance - newser.com
Published on: 2025-11-19 14:48:52 - newser.com
Analyzing net buyer seller activity in Artelo Biosciences Inc.2025 Analyst Calls & Real-Time Chart Breakout Alerts - newser.com
ARTL Stock Downgraded to Hold by Maxim Group | ARTL Stock News - GuruFocus
Applying Wyckoff theory to Artelo Biosciences Inc. stockMarket Performance Recap & Verified Technical Trade Signals - newser.com
Will Artelo Biosciences Inc. outperform the marketQuarterly Trade Report & Growth Focused Entry Reports - newser.com
Maxim Downgrades Artelo Biosciences to Hold From Buy - MarketScreener
Published on: 2025-11-19 04:37:27 - newser.com
What is the fair value of Artelo Biosciences Inc. stock nowEarnings Risk Report & Fast Gain Swing Alerts - newser.com
Artelo Biosciences Reports Increased Losses Amid R&D Investments - TipRanks
Published on: 2025-11-17 02:33:09 - newser.com
Will Artelo Biosciences Inc. see short term momentumCEO Change & Free AI Powered Buy and Sell Recommendations - newser.com
Analyzing Artelo Biosciences Inc. with risk reward ratio chartsGap Up & Fast Entry Momentum Trade Alerts - newser.com
Artelo Biosciences Revises Bylaws, Alters Governance Structure - The Globe and Mail
Measuring Artelo Biosciences Inc.’s beta against major indicesTrade Exit Summary & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-15 11:36:28 - newser.com
What momentum shifts mean for Artelo Biosciences Inc.Weekly Volume Report & Short-Term High Return Strategies - newser.com
Published on: 2025-11-14 04:04:42 - newser.com
Published on: 2025-11-14 02:11:25 - newser.com
Is Artelo Biosciences Inc. building a consolidation baseGold Moves & High Accuracy Trade Alerts - newser.com
Artelo Biosciences Reports Loss As R&D Spending Rises - Finimize
Analyzing recovery setups for Artelo Biosciences Inc. investorsJuly 2025 Review & Real-Time Chart Breakout Alerts - newser.com
Artelo Biosciences (ARTL) Advances Strategic Clinical Programs - GuruFocus
Artelo Biosciences Q3 net loss widens to $3.1 mln - MarketScreener
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results - The Manila Times
Artelo Biosciences (NASDAQ: ARTL) posts +6.4% weight gain vs -5.4% placebo with ART27.13 - Stock Titan
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):